Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

FDA approves diagnostic tool for MET-targeted lung cancer therapy

May 19, 2025 Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
News

Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria

May 19, 2025 Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)

A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …
News

Medable unveils oncology trial platform aimed at reducing logistical hurdles

May 16, 2025 Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials

Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …
News
researchers

Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU

May 16, 2025 Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia

Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
News

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

May 15, 2025 Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
News

Kaerus Bioscience secures FDA approval for rare genetic disorder treatment

May 15, 2025 Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes

Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …
News
handshake_2

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement

May 14, 2025 Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement

Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
News

Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing

May 14, 2025 Manufacturing and Production, Research and Development CGT production, Cell and Gene Therapy (CGT), Contraception, Pharmacy, Tozaro, advisory board

Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation of a Technical Advisory Board …
News

Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president

May 14, 2025 Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology

Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Appointment

Donato Spota appointed as chief financial officer at Eleva

May 14, 2025 Research and Development Eleva, Pharmacy, appointment, biopharma, chief financial officer (CFO)

German biopharma company, Eleva, has appointed Donato Spota as its new chief financial officer (CFO) and managing director to support …
Appointment
mental-health-3332122_960_720

Newron’s programme for treatment-resistant schizophrenia therapy approved

May 13, 2025 Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia

Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
News

Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy

May 12, 2025 Research and Development European Medicines Agency (EMA), FDA, Oncology, Thermosome

Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, …
News
researchers_credit_neusentis_pfizer

Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025

May 12, 2025 Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
News

Moderna expands use of AI-ready R&D platform

May 12, 2025 Business Services, Research and Development, Technical Consultancy AI, Benchling, Corporate, Moderna, R&D, digital transformation

Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by …
News
bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025 Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026